- Article metrics
- Last updated: Tue, 20 May 2025 17:51:44 Z
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
Access & Citations
-
- 1134
- Article Accesses
-
- Data not available
- Web of Science
-
- Data not available
- CrossRef
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.